Cite
HARVARD Citation
Pusceddu, S. et al. (n.d.). 1319PPost-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO). Annals of oncology. p. . [Online].